<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC4654359/results/search/disease/results.xml">
  <result pre="there was no observable trend. Drugs initially licensed to treat" exact="hepatitis" post="C had a longer duration of clinical development than"/>
  <result pre="now are radically changing the care of those infected by" exact="hepatitis" post="C.4 However, concerns have been expressed about the increasing"/>
  <result pre="and 2014 (inclusive) and specifically indicated for the treatment of" exact="viral disease" post="were identified along with their initial approved indication(s) from"/>
  <result pre="for HIV infection. The next most frequent initial indication was" exact="hepatitis" post="C infection (15%), followed by infection with cytomegalovirus (13%),"/>
  <result pre="hepatitis C infection (15%), followed by infection with cytomegalovirus (13%)," exact="hepatitis" post="B (8%), herpes simplex virus (4%), influenza virus (4%)"/>
  <result pre="(15%), followed by infection with cytomegalovirus (13%), hepatitis B (8%)," exact="herpes simplex" post="virus (4%), influenza virus (4%) and respiratory syncytial virus"/>
  <result pre="with cytomegalovirus (13%), hepatitis B (8%), herpes simplex virus (4%)," exact="influenza" post="virus (4%) and respiratory syncytial virus (2%, full details"/>
  <result pre="the initial indications for new drugs, those licensed to treat" exact="hepatitis" post="C infection had a longer duration of clinical development"/>
  <result pre="time taken for regulatory approval. In addition, drugs licensed for" exact="hepatitis" post="C appeared to spend longer in development than those"/>
 </snippets>
</snippetsTree>
